BIOMARIN PHARMACEUTICAL$38.46
-0.32
| Last Trade: |
38.46 |
| Trade Time: |
May 16 4:09 PM Eastern Daylight Time |
| Change: |
-0.32 (-0.83 %) |
| Prev Close: |
38.78 |
| Open: |
39.00 |
| Bid: |
37.46 |
| Ask: |
39.69 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/8/2012
|
Mueller Brian
|
VP, Corporate Controller
|
375
|
$17.89
|
1.29%
|
|
5/8/2012
|
BIENAIME JEAN JACQUES
|
Chief Executive Officer
|
15,000
|
$9.86
|
13.25%
|
|
5/8/2012
|
BIENAIME JEAN JACQUES
|
Chief Executive Officer
|
-15,000
|
$36.52
|
-11.70%
|
|
5/8/2012
|
Mueller Brian
|
VP, Corporate Controller
|
4,291
|
$17.33
|
17.80%
|
|
5/8/2012
|
Mueller Brian
|
VP, Corporate Controller
|
417
|
$17.54
|
1.76%
|
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (BMRN), click here.
-
Explore five stocks making new highs. Is this a case of overvalue, or could investors buy high and sell even higher?
Read More »
-
In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
Read More »
-
If biotech companies are buying each other, should investors get in on the action?
Read More »
-
Despite positive Phase 3 results, this medicine-maker's valuation is excessive and its new drug won't make it to market for a year.
Read More »
-
Stocks that can string together many quarters of positive earnings surprises are usually rewarded. Learn why the market loves a surprise.
Read More »
Free Reports
|
|
